Mechanistic studies will clearly be important to understand the contribution of these mutations and expression changes to leukemogenesis and possibly to allow for the development of personalized therapies based on specific SNF2 or CRC targets. The gene discussed is SMARCA2; the disease is colorectal carcinoma.